Vtesse Inc., a new rare disease company focused on pushing a potentially transformational lysosomal storage disease (LSD) drug into pivotal testing this year, has raised a $25 million series A round from the syndicate of life sciences investors behind Cydan Development Inc., an orphan drug accelerator building a glide-way for therapies targeting monogenic diseases.